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iscussion
r John D. Puskas (Atlanta, Ga). My congratulations to you and
our colleagues from Hyderabad for enrolling 116 patients in 16
onths in a randomized surgical trial. That may be a world record
or a single center.
Your study has again demonstrated, as others have, that OPCAB
s associated with a significant decrease in inotrope dependence,
ransfusion, chest tube drainage, and ventilation time. You have also
ound a trend toward a decrease in death and postoperative hemodi-
lysis, but your primary end point was to focus on the increase in
erum creatinine and decline in GFR after CPB, and you demon-
trated a benefit for OPCAB that was greatest in diabetic patients and
n hypertensive patients. I have several questions for you.
First, how well did you control the mean CPB perfusion pres-
ures during the on-pump cases, and how did that compare with the
ean arterial pressures during off-pump surgical procedures? In
ther words, is it a matter of perfusion of the body during these two
perations or is it something else related to the pump that would
xplain your differences?
Dr Sajja. Thank you, Dr Puskas, for your comments and ques-
ions. In the on-pump group, we maintained the systemic mean
rterial pressure at around 65 to 70 mm Hg, while in the off-pump
roup, most of the time the mean pressure was about 70 to 75 mm Hg.
sually, when we revascularize the anterior vessels, the mean pres-
ure is much higher than what we maintain on the pump.
Dr Puskas. You found after surgery that there was an increased
ependence on inotropes in the on-pump group relative to the
ff-pump group. Were you able to examine those subsets of
atients who required inotropes in both groups and compare renal
utcomes between these subgroups? In other words, is it a matter
f inotrope dependence after the pump run that explains the
ifference in renal outcomes or is it something else?
Dr Sajja. We have analyzed the inotropic requirements be-
ween the two groups and found a significant number of patients
equire inotropes in the on-pump group, but we have not analyzed
hether inotropic requirement is an independent predictor of renal
ailure or not. The myocardial protection that occurred during
ff-pump is better than on-pump CABG.
Dr Richard J. Shemin (Boston, Mass). I think this paper is
lso important in that you emphasize that 30% of patients with
ormal serum creatinine values actually have renal disease. But my
eal question is, in the on-pump group compared with the off-pump
roup, how many conversions did you have from off-pump to
n-pump and did you analyze the data on an intent-to-treat basis if
ou did have such conversions?
Dr Sajja. Fortunately, none of the patients in this study in the
ff-pump group needed conversion to CPB. We have been doing the
ff-pump surgery since 1996 and the technique has been standardized.
Dr Ralph J. Damiano (St Louis, Mo).I would like to echo the
ongratulations from the other discussants, Dr Sajja, on a well-
erformed randomized study. My question is really a follow-up on
r Puskas’s question. Did you look at the use of nephrotoxic drugs
etween each group? In particular, was aprotinin used more often
n the on-pump group? How about other drugs like alpha agonists,
and Cardiovascular Surgery ● Volume 133, Number 2 387
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CDhich clearly could have an adverse effect on renal function?
ould this potentially explain the difference as opposed to the use
f the pump itself?
Finally, could you share with us whether the advantages of the
ff-pump technique also extend to the dialysis-dependent group in
our experience?
Dr Sajja. Thank you for your questions. Regarding the use of
ephrotoxic drugs, we have avoided using aminoglycosides and
ther nephrotoxic drugs in all of these patients, whether they are88 The Journal of Thoracic and Cardiovascular Surgery ● Febriven N-acetylcysteine preoperatively and for 5 days postopera-
ively.
We do not have much experience with dialysis-dependent
atients undergoing CABG, only a couple of cases; therefore, I
annot comment on the advantages of the off-pump technique in
his subset of patients.
Dr Damiano. Do you use aprotinin in the on-pump group?
Dr Sajja. Only 2 patients received aprotinin in the on-pump
roup and none in the off-pump group. The use of aprotinin is not
reated on-pump or off-pump, but in all these patients we have common in our institution.uary 2007
